Trade

with

Sucampo Pharmaceuticals Inc
(NASDAQ: SCMP)
AdChoices
8.42
+0.41
+5.12%
After Hours :
8.42
0.00
0.00%

Open

8.15

Previous Close

8.01

Volume (Avg)

166.06k (83.87k)

Day's Range

8.02-8.63

52Wk Range

5.80-11.00

Market Cap.

354.79M

Dividend Rate ( Yield )

-

Beta

1.53

Shares Outstanding

44.29M

P/E Ratio (EPS)

61.35 (0.13)

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
  • Management effectiveness
Industry Drug Manufacturers – Specific & Generic
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 89.59M

    • Net Income

    • 6.42M

    • Market Cap.

    • 354.79M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • 6.11

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.53

    • Forward P/E

    • 19.19

    • Price/Sales

    • 3.75

    • Price/Book Value

    • 5.11

    • Price/Cash flow

    • 105.26

      • EBITDA

      • 13.73M

      • Return on Capital %

      • 4.05

      • Return on Equity %

      • 9.54

      • Return on Assets %

      • 4.05

      • Book Value/Share

      • 1.57

      • Shares Outstanding

      • 44.29M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Buy
        • 1 Year Price Target

        • 10.67

        • Credit Rating

        • -

        • Analysts

        • 3

        • EPS Estimate

        • 0.39

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • -10.90

          • 7.67

          • Net Income

            YTD/YTD (last year)

          • 32.70

          • -26.33

          • Net Income

            Q/Q (last year)

          • -74.20

          • 197.54

          • Sales (Revenue)

            5-Year Annual Average

          • -4.39

          • -5.42

          • Net Income

            5-Year Annual Average

          • -23.80

          • 3.16

          • Dividends

            5-Year Annual Average

          • -

          • -0.13

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 82.15

            • 64.72

            • Pre-Tax Margin

            • 7.80

            • 13.77

            • Net Profit Margin

            • 6.11

            • 10.84

            • Average Gross Margin

              5-Year Annual Average

            • 59.30

            • 67.80

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -3.80

            • 15.58

            • Average Net Profit Margin

              5-Year Annual Average

            • -4.80

            • 343.47B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 0.31

              • 0.33

              • Current Ratio

              • 2.81

              • 1.52

              • Quick Ratio

              • 2.03

              • 0.87

              • Interest Coverage

              • 5.22

              • 6.77

              • Leverage Ratio

              • 2.05

              • 1.91

              • Book Value/Share

              • 1.57

              • 16.21

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • 61.35

                • 63.69

                • P/E Ratio 5-Year High

                • 84.32

                • 237.47

                • P/E Ratio 5-Year Low

                • 21.08

                • 19.71

                • Price/Sales Ratio

                • 3.75

                • 3.64

                • Price/Book Value

                • 5.11

                • 3.39

                • Price/Cash Flow Ratio

                • 105.26

                • 21.79

                • Key Metrics

                • Company

                  • Shares Short

                    as of -

                  • -

                  • Short Ratio

                    as of -

                  • -

                  • Short % of Float

                    as of -

                  • -

                  • Shares Short

                    prior month

                  • -

                  • Trailing Annual Dividend Yield

                  • -

                  • 5 Year Average Dividend Yield

                  • -

                  • Key Metrics

                  • Company

                    • Payout Ratio

                    • -

                    • Dividend Date

                    • -

                    • Ex-Dividend Date

                    • -

                    • Last Split Factor

                      new per old

                    • -

                    • Last Split Date

                    • -

                    • Key Metrics

                    • Company

                    • Industry

                      • Return on Equity %

                        (5-Year Average)

                      • 9.54

                        (-3.40)

                      • 7.86

                        (9.58)

                      • Return on Assets %

                        (5-Year Average)

                      • 4.05

                        (-1.10)

                      • 4.14

                        (5.54)

                      • Return on Capital %

                        (5-Year Average)

                      • 6.17

                        (-0.60)

                      • 5.59

                        (7.66)

                      • Income/Employee

                      • 72.94k

                      • 27.79k

                      • Inventory Turnover

                      • 6.19

                      • 1.80

                      • Asset Turnover

                      • 0.66

                      • 0.38

                      Current Historical
                      Financials
                      • Income Statement
                      • Balance Sheet
                      • Cash Flow
                      Operating Income
                      9.20M
                      Operating Margin
                      10.26
                      Total Equity
                      -
                      Retained Earnings
                      -
                      Free Cashflow
                      -
                      Price/Cashflow
                      105.26
                      Ownership

                      Institutional Ownership

                      24.79%

                      Top 10 Institutions

                      17.91%

                      Mutual Fund Ownership

                      12.89%

                      Float

                      33.84%

                      5% / Insider Ownership

                      1.57%

                      Corporate insiders or major stockholders reporting trading activity in the stock.

                      Top Mutual Fund Owners

                      Top Institutional Owners

                      Mutual Fund Name

                      Institution Name

                      • Mutual Fund Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Vanguard VIF Small Comp Gr

                      •  

                        753,100

                      • 0.00

                      • 1.70

                      • SEB Concept BioTech

                      •  

                        609,600

                      • 27.45

                      • 1.38

                      • iShares Nasdaq Biotechnology

                      •  

                        577,096

                      • -1.85

                      • 1.60

                      • Vanguard Extended Market Index Fund

                      •  

                        325,858

                      • 0.97

                      • 0.74

                      • DFA US Small Cap Value II Portfolio

                      •  

                        277,919

                      • 0.00

                      • 0.63

                      • iShares Russell 2000 (AU)

                      •  

                        270,671

                      • -0.90

                      • 0.75

                      • Vanguard Total Stock Mkt Idx

                      •  

                        250,330

                      • 0.00

                      • 0.57

                      • Vanguard US Discoveries Fund

                      •  

                        213,239

                      • -2.25

                      • 0.48

                      • Putnam Small Cap Value Fund

                      •  

                        180,100

                      • 1.98

                      • 0.41

                      • NVIT Multi-Manager Small Company Fund

                      •  

                        144,500

                      • 0.00

                      • 0.33

                      • Institution Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Visium Asset Management LLC

                      •  

                        1,806,000

                      • +2.50%

                      • 4.08

                      • Granahan Investment Management Inc..

                      •  

                        1,389,775

                      • +10.60%

                      • 3.14

                      • BlackRock Fund Advisors

                      •  

                        953,191

                      • +4.74%

                      • 2.15

                      • Dimensional Fund Advisors, Inc.

                      •  

                        904,599

                      • +2.41%

                      • 2.04

                      • Putnam Investment Management,LLC

                      •  

                        776,724

                      • -2.71%

                      • 1.75

                      • Vanguard Group, Inc.

                      •  

                        616,217

                      • +12.02%

                      • 1.39

                      • SEB Investment Management AB

                      •  

                        609,600

                      • +27.45%

                      • 1.38

                      • Millennium Management LLC

                      •  

                        299,819

                      • -31.45%

                      • 0.68

                      • Pictet Asset Management SA

                      •  

                        286,900

                      • +44.39%

                      • 0.65

                      • USAA Investment Management Company

                      •  

                        286,550

                      • 0.00%

                      • 0.65

                      Company Profile

                      Sector

                      Healthcare

                      Industry

                      Drug Manufacturers – Specific & Generic

                      Type

                      Aggressive Growth

                      Style

                      Small Growth

                      Sucampo Pharmaceuticals, Inc. was incorporated on 05 December 1996. The Company is a biopharmaceutical company engaged in research, discovery, development and commercialization of proprietary drugs based on ion channel activators kno...morewn as prostones. The Company is engaged in developing and/or commercializing prostone-based drugs to treat gastrointestinal, ophthalmic, neurologic, and oncology-based inflammatory disorders, and also considering other potential therapeutic applications of its drug technologies. It generates revenue primarily from product royalties, development milestone payments, clinical development activities and product sales. The Company seeks additional regulatory approvals and additional indications for AMITIZA (lubiprostone), RESCULA (unoprostone isopropyl) and other compounds. I...morets operations are conducted through subsidiaries based in Japan, the United States, Switzerland, the United Kingdom and Luxembourg. Its reportable geographic segments are Asia, the Americas and Europe. The Company has over 525 active issued patents based on its proprietary prostone technology. It holds all commercialization rights for unoprostone isopropyl except for Japan, Korea, Taiwan and the People’s Republic of China.lessless

                      Key People

                      Mr. Peter Greenleaf

                      CEO/Director

                      Dr. Daniel P. Getman, PhD

                      Director/Chairman of the Board

                      Dr. Ryuji Ueno,M.D.

                      Chief Scientific Officer/Co-Founder

                      Cary J. Claiborne

                      CFO

                      Thomas J. Knapp

                      Executive VP/Other Executive Officer/Secretary

                      • Sucampo Pharmaceuticals Inc

                      • 4520 East-West Highway

                      • Bethesda, MD 20814

                      • USA.Map

                      • Phone: +1 301 961-3400

                      • Fax: +1 301 961-3440

                      • sucampo.com

                      Incorporated

                      1996

                      Employees

                      77

                      Send Feedback

                      We appreciate your input!

                      • I'm having trouble signing into my Microsoft account

                      • I’m having problems with the services stripe (Mail, Facebook, etc.)

                      • There is an issue with my weather information

                      • I see an error in the content

                      • Other

                      Please give an overall site rating: